---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-006821"
form_type: "8-K"
ticker: "AZTA"
cik: "0000933974"
company_name: "Azenta, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:58:06.694055+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Azenta acquires UK Biocentre for GBP 20.5M to expand European biorepository footprint

## Summary
- Total consideration of GBP 20.5M net of cash, including up to GBP 1.8M contingent milestone payments.
- UK Biocentre generated approx GBP 15.3M revenue in twelve months ended Sep 30, 2025.
- Deal expected to be dilutive to FY2026 Adj EBITDA margin by ~35bps, accretive to FY2027/2028 revenue growth and margin.
- UK Biocentre will operate as European hub, adding automated high-throughput capacity and BioArc™ Ultra deployment.
- Conference call to discuss transaction scheduled for March 10, 2026 at 10:00 am ET.

## SEC filing metadata
- accession: 0001437749-26-006821
- form_type: 8-K
- ticker: AZTA
- cik: 0000933974
- company_name: Azenta, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/933974/000143774926006821/0001437749-26-006821-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/933974/000143774926006821/azta20260303_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-006821
- JSON: https://secwatch.observer/filing/0001437749-26-006821.json
- Plain text: https://secwatch.observer/filing/0001437749-26-006821.txt

## Key facts
- Material Agreements
  Azenta, Inc. entered into Share Purchase Agreement with UK Biocentre Limited valued at GBP 20.5 million (effective 2026-03-04).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: UK Biocentre Limited
  - Value: GBP 20.5 million
  - Effective: 2026-03-04
  source text: On March 4, 2026, Azenta UK Ltd., a wholly owned subsidiary of Azenta, Inc. (“Azenta” or the “Company”) entered into a definitive Share Purchase Agreement (“Agreement”) under which Azenta UK Ltd. acquired all the issued and outstanding share capital of UK Biocentre Limited (“UK Biocentre”), a provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom.
  evidence_url: https://www.sec.gov/Archives/edgar/data/933974/000143774926006821/0001437749-26-006821-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.